Key terms
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PBYI news
Mar 20
8:37am ET
FDA allows Puma to proceed under IND with alisertib development for BC
Mar 19
10:17pm ET
Puma Biotechnology says court denied AstraZeneca’s motion for invalidity
Mar 01
8:37am ET
Buy Rating on Puma Biotechnology Amid Financial Challenges and Drug Advancement Prospects
Mar 01
8:25am ET
Puma Biotechnology price target lowered to $7 from $8 at H.C. Wainwright
Mar 01
3:00am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Puma Biotechnology (PBYI) and MoonLake Immunotherapeutics (MLTX)
Feb 29
11:05pm ET
Puma Biotechnology: Hold Rating Justified by Underwhelming Sales and Limited Growth Outlook
Feb 29
4:19pm ET
Puma Biotechnology sees Fy24 revenue $214M-$225M, consensus $244.7M
Feb 29
4:18pm ET
Puma Biotechnology sees Q1 revenue $40.5M-$43M, one estimate 56.5M
Feb 29
4:18pm ET
Puma Biotechnology reports Q4 EPS 31c, consensus 30c
Feb 13
11:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Puma Biotechnology (PBYI), ESSA Pharma (EPIX)
Jan 19
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 18
11:32am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for PBYI
PBYI Financials
Key terms
Ad Feedback
PBYI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PBYI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range